<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431234</url>
  </required_header>
  <id_info>
    <org_study_id>P111105</org_study_id>
    <nct_id>NCT02431234</nct_id>
  </id_info>
  <brief_title>Arterial Calcification in the Diabetes</brief_title>
  <acronym>DIACART</acronym>
  <official_title>Study of the Mechanisms of the Arterial Calcification of the Members Subordinates in the Diabetes (Implication of the System RANK / RANKL / OSTEOPROTEGERINE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The blood concentration of the protein RANKL could be predictive of the calcification of the&#xD;
      leg arteries, which is a major complication occurring during diabetes. The objective of the&#xD;
      DIACART study is to show that blood RANKL concentration predict the progression of&#xD;
      calcification of the leg arteries in diabetic patients, independently of other cardiovascular&#xD;
      risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Peripheral arterial disease (PAD) is the primary major amputation risk factor&#xD;
      in diabetes. The PAD is particularly common among diabetic patients at high cardiovascular&#xD;
      risk (20-30% of coronary patients have PAD). The calcification of atherosclerotic plaque and&#xD;
      media leg arteries contributes to narrowing of the arterial lumen and exposes the diabetic&#xD;
      patient to critical limb ischemia. The receptor RANK (Receptor Activator for Nuclear Factor κ&#xD;
      B) and its ligand RANKL form a complex which initially was described as being involved in&#xD;
      bone metabolism by activating osteoclasts but the RANK / RANKLigand system could also be&#xD;
      involved in the process calcification and arterial obstruction, especially in the lower&#xD;
      limbs. Currently there is anti-RANKL antibody used in humans that could possibly slow down&#xD;
      this process. But it is necessary to prove the involvement of this system in PAD in diabetic&#xD;
      patients at high cardiovascular risk before proposing a therapeutic trial.&#xD;
&#xD;
      Assumptions: the concentration of RANKL could be predictive of calcification of leg arteries&#xD;
      in diabetes Main objective: To show that serum RANKL concentrations predict the progression&#xD;
      of calcification of the leg arteries in diabetic patients, independently of other&#xD;
      cardiovascular risk factors.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To show the link between other proteins of bone remodeling, markers of inflammation and&#xD;
           glycation, and calcification of leg arteries.&#xD;
&#xD;
        -  Measuring the rate of calcification leg arteries.&#xD;
&#xD;
        -  Phenotype diabetic patients who have the highest rate of calcification. Primary Outcome:&#xD;
           Predictive power of serum RANKL concentration at T0 on the progression of calcification&#xD;
           of leg arteries between T0 and T24 months.&#xD;
&#xD;
      Methodology: prospective observational study. The calcium score of leg arteries will be&#xD;
      evaluated by a scanner at T0 and 24 months.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  type 2 diabetes&#xD;
&#xD;
        -  women over 60&#xD;
&#xD;
        -  men over 50 years&#xD;
&#xD;
        -  men and women with known coronary artery disease Non-inclusion criteria:&#xD;
&#xD;
        -  severe renal failure&#xD;
&#xD;
        -  immunodeficiency&#xD;
&#xD;
        -  acute infectious or inflammatory disease&#xD;
&#xD;
        -  history of bypass surgery or sub-popliteal angioplasty Number of subjects required: 188&#xD;
           patients will be included. Total study duration: 24 months Inclusion period: 24 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum RANKL concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum RANKL concentrations to predict the progression of calcification of the leg arteries in diabetic patients, (independently of other cardiovascular risk factors)</description>
  </primary_outcome>
  <enrollment type="Anticipated">169</enrollment>
  <condition>Diabetic Vascular Diseases</condition>
  <condition>Arteriosclerosis Obliterans</condition>
  <condition>Monckeberg Medial Calcific Sclerosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum RANKL</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women with type 2 diabetes and known coronary artery disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  type 2 diabetes&#xD;
&#xD;
          -  women over 60&#xD;
&#xD;
          -  men over 50 years&#xD;
&#xD;
          -  men and women with known coronary artery disease&#xD;
&#xD;
        Non-Exclusion criteria:&#xD;
&#xD;
          -  severe renal failure&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  acute infectious or inflammatory disease&#xD;
&#xD;
          -  history of bypass surgery or sub-popliteal angioplasty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Bourron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Arterial calcification</keyword>
  <keyword>Mediacalcosis</keyword>
  <keyword>Calcium score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis Obliterans</mesh_term>
    <mesh_term>Diabetic Angiopathies</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Monckeberg Medial Calcific Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

